Improved Cryopreservation of hES and IPS Cells

Isis Project No 4039/4122 Oxford researchers have developed cryopreservation methods for cryopreserving and recovering hES and iPS cells, resulting in improved cell survival and recovery rates.

Marketing Opportunity
hES cells have become potential sources for many clinical applications, ranging from drug discovery and regenerative medicine to tissue replacement after injury or disease. The market potential of tissue engineering alone is estimated to exceed $10B by 2013 (“Tissue engineering & stem cell technology report,” Bharat Book Bureau, 2007) . Oxford researchers have developed novel, improved cryopreservation methods for recovering hES cells and iPS cells. The intellectual property also covers cryopreservation media for stem cells, animal cells and mesenchymal stem (MS) cells.

The Oxford Invention
Human embryonic stem (hES) cells have an unlimited capacity for self-renewal and unique developmental potential to differentiate themselves into over 200 cell types of the human body. However, an essential prerequisite for successful applications of hES cells is to develop efficient cryopreservation methods to improve the current poor cell survival and recovery rates following cryopreservation. The Oxford invention is a novel cryopreservation protocol for cryopreserving and recovering hES cells and subsequent culture, enabling higher cell viability and maintaining an undifferentiated status following cryopreservation. Such efficient cell cryopreservation methods can be equally applied to cryopreservation of induced pluripotent stem (iPS) cells.

Patent Status
This Oxford invention is the subject of a patent application, and Isis is keen to talk to companies interested in developing the commercial opportunity. Please contact the Isis Project Manager.

Attached files:


Type of Offer: Licensing



« More Genetics Patents

---